ACTU (Actuate Therapeutics) Ending Cash Position : $8.64 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Ending Cash Position?

Actuate Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was $8.64 Mil.

Actuate Therapeutics's quarterly Ending Cash Position increased from Jun. 2024 ($0.35 Mil) to Sep. 2024 ($13.52 Mil) but then declined from Sep. 2024 ($13.52 Mil) to Dec. 2024 ($8.64 Mil).

Actuate Therapeutics's annual Ending Cash Position declined from Dec. 2022 ($20.45 Mil) to Dec. 2023 ($2.96 Mil) but then increased from Dec. 2023 ($2.96 Mil) to Dec. 2024 ($8.64 Mil).

Actuate Therapeutics Ending Cash Position Historical Data

The historical data trend for Actuate Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Ending Cash Position Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Ending Cash Position

20.45

2.96

8.64

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial				2.96	2.07	0.35	13.52	8.64

Actuate Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Actuate Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.959	+	5.683
	=	8.64

Actuate Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	13.523	+	-4.881
	=	8.64

Actuate Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.